PACB

Pacific Biosciences of California Inc

Add to Watchlist

Advanced Chart

1.370

-0.02(-1.439%)1D

Overview
Forecast
Valuation
Earnings

High

1.440

Open

1.440

VWAP

1.38

Vol

4.39M

Mkt Cap

411.12M

Low

1.350

Amount

6.06M

EV/EBITDA(TTM)

Total Shares

272.36M

714.22M

EV/OCF(TTM)

P/S(TTM)

2.53

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

36.45M

+1.22%

39.60M

-0.93%

42.35M

+7.98%

Estimates Revision

The market is revising Downward the revenue expectations for Pacific Biosciences of California, Inc. (PACB) for FY2025, with the revenue forecasts being adjusted by -2.56% over the past three months. During the same period, the stock price has changed by 20.18%.

Revenue Estimates for FY2025

Revise Downward

-2.56%

In Past 3 Month

Stock Price

Go Up

+20.18%

In Past 3 Month

8 Analyst Rating

57.66% Upside

Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.16 USD with a low forecast of 1.25 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

0 Sell

Moderate Buy

57.66% Upside

Current: 1.370

Low

1.25

Averages

2.16

High

3.00

57.66% Upside

Current: 1.370

Low

1.25

Averages

2.16

High

3.00

Barclays

Luke Sergott

Equal Weight

downgrade

2025-06-25

Reason

Barclays

Luke Sergott

Price Target

2025-06-25

downgrade

Equal Weight

Reason

Piper Sandler

Neutral

downgrade

2025-05-15

Reason

Piper Sandler

Price Target

2025-05-15

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on PacBio to $1.25 from $2 following quarterly results. The firm keeps a Neutral rating on the shares.

Canaccord Genuity

Kyle Mikson

Strong Buy

Maintains

2025-04-10

Reason

Canaccord Genuity

Kyle Mikson

Price Target

2025-04-10

Maintains

Strong Buy

Reason

Scotiabank

Sung Ji Nam

Buy

Maintains

$6 → $2

2025-03-25

Reason

Scotiabank

Sung Ji Nam

Price Target

$6 → $2

2025-03-25

Maintains

Buy

Reason

Scotiabank analyst Sung Ji Nam lowered the firm's price target on PacBio to $2 from $6 and keeps an Outperform rating on the shares. The company's FY24 was disappointing, and this year could have driven significant revenue reacceleration had it not been for near-term U.S. academic funding uncertainty dampening growth, the analyst tells investors. The firm continues to believe the company is well positioned to innovate faster, cheaper, easier, and more insightful NGS capabilities.

Piper Sandler

David Westenberg

Hold

Reiterates

$2.5 → $2

2025-02-20

Reason

Piper Sandler

David Westenberg

Price Target

$2.5 → $2

2025-02-20

Reiterates

Hold

Reason

Piper Sandler lowered the firm's price target on PacBio to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares.

Goldman Sachs

Matthew Sykes

Hold

Maintains

$1.75 → $1.5

2025-02-18

Reason

Goldman Sachs

Matthew Sykes

Price Target

$1.75 → $1.5

2025-02-18

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pacific Biosciences of California Inc (PACB.O) is -2.13, compared to its 5-year average forward P/E of -2.27. For a more detailed relative valuation and DCF analysis to assess Pacific Biosciences of California Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.27

Current PE

-2.13

Overvalued PE

45.85

Undervalued PE

-50.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.61

Current EV/EBITDA

-4.64

Overvalued EV/EBITDA

-1.10

Undervalued EV/EBITDA

-26.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.05

Current PS

2.79

Overvalued PS

30.40

Undervalued PS

1.70

Financials

Annual

Quarterly

FY2025Q1

YoY :

-4.27%

37.15M

Total Revenue

FY2025Q1

YoY :

+419.41%

-422.97M

Operating Profit

FY2025Q1

YoY :

+445.01%

-426.08M

Net Income after Tax

FY2025Q1

YoY :

+396.55%

-1.44

EPS - Diluted

FY2025Q1

YoY :

-36.60%

-50.45M

Free Cash Flow

FY2025Q1

YoY :

-6600.00%

-967.20

Gross Profit Margin - %

FY2025Q1

YoY :

-3.31%

-120.20

FCF Margin - %

FY2025Q1

YoY :

+469.31%

-1.15K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

754.0K

USD

6-9

Months

70.0K

USD

0-12

Months

139.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

312.1K

Volume

6-9

Months

2.4M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

20.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

754.0K

USD

6-9

Months

70.0K

USD

0-12

Months

139.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

PACB News & Events

Events Timeline

2025-06-02 (ET)

2025-06-02

10:02:53

PacBio partners with Target ALS to launch genome sequencing initiative

2025-05-22 (ET)

2025-05-22

09:08:38

PacBio appoints Haorui Gene as official distributor in China

2025-05-12 (ET)

2025-05-12

10:59:04

PacBio board: Independent investigation concludes allegations unsubstantiated

News

2.0

07-11NASDAQ.COM

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

2.0

06-30NASDAQ.COM

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know

6.0

06-25Benzinga

Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $1.5

People Also Watch

Hudson Pacific Properties Inc

Mereo BioPharma Group PLC

EQV Ventures Acquisition Corp

AA Mission Acquisition Corp

SIGA Technologies Inc

Central Garden & Pet Co

40.120

USD

-2.05%

FAQ

What is Pacific Biosciences of California Inc (PACB) stock price today?

The current price of PACB is 1.37 USD — it has decreased -1.44 % in the last trading day.

PACB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PACB News & Events

Events Timeline

News

People Also Watch

FAQ

What is Pacific Biosciences of California Inc (PACB) stock price today?

What is Pacific Biosciences of California Inc (PACB)'s business?

What is the price predicton of PACB Stock?

What is Pacific Biosciences of California Inc (PACB)'s revenue for the last quarter?

What is Pacific Biosciences of California Inc (PACB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pacific Biosciences of California Inc (PACB)'s fundamentals?

How many employees does Pacific Biosciences of California Inc (PACB). have?

What is Pacific Biosciences of California Inc (PACB) market cap?